TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20873909
Drug: CCAL (computer-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCAL (computer-assisted cognitive behavioral therapy)
Study: 20873909
Drug: ICBT (individual
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICBT (individual cognitive behavioral therapy)
Study: 16637791
Drug: Electronic tool
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic tool for metformin monitoring
Study: 8646249
Drug: Triglyceride-heparin infusion
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglyceride-heparin infusion
Study: 29274034
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum (COL) 20 g/day
Study: 19437334
Drug: Aspirin 160
Normalized name: aspirin 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 160 mg per day for 7‐10 days
Study: 18640465
Drug: Pitavastatin 2
Normalized name: PITAVASTATIN 2MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 2 mg/d
Study: 10409530
Drug: sotalol 80
Normalized name: sotalol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sotalol 80 mg twice daily
Study: 7650808
Drug: Paternal white
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paternal white blood cell immunization (published studies, random treatment effect model)
Study: 7650808
Drug: Paternal white
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paternal white blood cell immunization (individual patient data, random treatment effect model)
Study: 7650808
Drug: Paternal white
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paternal white blood cell immunization (unpublished trials, random treatment effect model)
Study: 1692988
Drug: Galanin (Gal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galanin (Gal) plus growth hormone‐releasing hormone (GHRH)
Study: 7417900
Drug: Topical antibiotic
Normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antibiotic spray (neomycin sulfate, polymyxin B sulfate, zinc bacitracin)
Study: 22930789
Drug: Atomoxetine (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (target dose: 1.2 mg/kg per day)
Study: 17531918
Drug: Inotropic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inotropic drugs
Study: 2672774
Drug: Sucrose (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (45 g, 9% of total daily energy) added to diet
Study: 2672774
Drug: Aspartame (162
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (162 mg) added to diet
Study: 31630479
Drug: Apixaban 10
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 10 mg twice daily for seven days followed by 5 mg twice daily for six months
Study: 31630479
Drug: Dalteparin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (200 IU/kg for one month followed by 150 IU/kg once daily)
Study: 25697717
Drug: 5-mm injection
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-mm injection depth of insulin lispro (0.25 U/kg)
Study: 25697717
Drug: 8-mm injection
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-mm injection depth of insulin lispro (0.25 U/kg)
Study: 23978642
Drug: Low-dose salbutamol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose salbutamol (1μg)
Study: 9138658
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran fiber (2.0 or 13.5 g/day)
Study: 9138658
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (250 or 1500 mg/day)
Study: 9138658
Drug: Placebo (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2.0 g of wheat bran fiber plus 250 mg of calcium carbonate during 3-month run-in)
Study: 1381022
Drug: Metoprolol 50
Normalized name: metoprolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 50 mg b.i.d.
Study: 29154553
Drug: Gender‐neutral Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gender‐neutral Cognitive Behavioral Therapy (GN‐CBT)
Study: 25886088
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream combined with salicylic acid 15%
Study: 2741976
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg, four times daily)
Study: 2741976
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg, four times daily)
Study: 16931609
Drug: Glutamine-enriched enteral
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-enriched enteral nutrition (0.3 g/kg/d)
Study: 15451912
Drug: Fasting insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fasting insulin levels, BMI, waist-to-hip ratio
Study: 15451912
Drug: Two-hour postload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-hour postload plasma glucose (2-h PG), serum insulin, fasting plasma glucose
Study: 15451912
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of systolic and diastolic blood pressure
Study: 15451912
Drug: Urinary albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary albumin excretion rate
Study: 9255764
Drug: Skinner herpes
Normalized name: herpesvirus 2, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skinner herpes simplex vaccine (NFU.Ac.HSV‐1(S‐)MRC) administered at 0, 1, and 2 months
Study: 9255764
Drug: Skinner herpes
Normalized name: herpesvirus 2, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skinner herpes simplex vaccine (NFU.Ac.HSV‐1(S‐)MRC)
Study: 9255764
Drug: Skinner herpes
Normalized name: herpesvirus 2, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skinner herpes simplex vaccine (NFU.Ac.HSV‐1(S‐)MRC
Study: 7685425
Drug: Verapamil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (80 mg, four doses orally starting the night before ESWL)
Study: 28370401
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (2 g/m2 daily on days 1 and 2) plus G-CSF and pre-emptive/rescue plerixafor
Study: 28370401
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (2 g/m2 daily on days 1 and 2) plus G-CSF
Study: 28370401
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (2 g/m2 daily on days 1 and 2)
Study: 21716073
Drug: Dolutegravir 2
Normalized name: dolutegravir 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 2 mg
Study: 19194375
Drug: Combined cholinergic
Normalized name: PARASYMPATHOMIMETICS (CHOLINERGICS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined cholinergic receptor blockade (scopolamine 4 microg/kg bodyweight intravenously and mecamylamine 5 mg orally)
Study: 19194375
Drug: Combined cholinergic
Normalized name: PARASYMPATHOMIMETICS (CHOLINERGICS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined cholinergic receptor blockade
Study: 16704676
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of splinting, tendon‐ and nerve‐gliding exercises
Study: 16704676
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment in combination with splinting
Study: 16704676
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ultrasound, splinting, tendon‐ and nerve‐gliding exercises
Study: 16704676
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of splinting, exercise and ultrasound therapy
Study: 15679252
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation with surgery
Study: 15679252
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation without surgery
Study: 11316542
Drug: Hfx RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hfx RT with daily carboplatin/etoposide (50 mg each)
Study: 11316542
Drug: Hfx RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hfx RT with daily carboplatin/etoposide (30 mg each) and weekend carboplatin/etoposide (100 mg each)
Study: 9027276
Drug: Allopurinol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (20 mg/kg/day, three 100-mg tablets four times daily for 28 days)
Study: 9027276
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three placebo tablets four times daily for 28 days)
Study: 9027276
Drug: Glucantime (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucantime (20 mg of intramuscular antimony/kg per day for 20 days)
Study: 8276046
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of SDZ MKS 492 (40 mg)
Study: 8276046
Drug: Inhaled SDZ
Normalized name: SDZ MSL 109
DrugBank: Sevirumab (DB17771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled SDZ MKS 492 (12 mg)
Study: 8276046
Drug: Inhaled SDZ
Normalized name: SDZ MSL 109
DrugBank: Sevirumab (DB17771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled SDZ MKS 492 (10 mg and 20 mg)
Study: 8276046
Drug: Inhaled SDZ
Normalized name: SDZ MSL 109
DrugBank: Sevirumab (DB17771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled SDZ MKS 492
Study: 31919695
Drug: Parent-Based Treatment
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-Based Treatment (PBT)
Study: 29716471
Drug: Standard-mother-infant treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-mother-infant treatment (TAU)
Study: 26935334
Drug: Levofloxacin inhalation
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin inhalation solution (LIS) 240mg twice daily for 28 days
Study: 26935334
Drug: Levofloxacin inhalation
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin inhalation solution (LIS)
Study: 20378601
Drug: Sitaxsentan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitaxsentan (100 mg·day(‐1) for 7 days)
Study: 14640991
Drug: GH (0.88+/‐0.13
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH (0.88+/‐0.13 mg)
Study: 14640991
Drug: GH+acipimox 250
Normalized name: acipimox 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH+acipimox 250 mg b.i.d.
Study: 8853083
Drug: 6 to
Normalized name: vitamin B6 Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 to 7% sevoflurane in 66% nitrous oxide/28% oxygen by face mask until tracheal intubation (treatment 1)
Study: 8853083
Drug: 6 to
Normalized name: vitamin B6 Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 to 7% sevoflurane without nitrous oxide to tracheal intubation (treatment 2)
Study: 8853083
Drug: 6 to
Normalized name: vitamin B6 Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 to 7% sevoflurane in 66% nitrous oxide/28% oxygen by face mask until laryngeal mask airway insertion (treatment 3)
Study: 1535877
Drug: High-dose ionic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ionic contrast medium (diatrizoate sodium)
Study: 1535877
Drug: High-dose nonionic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nonionic contrast medium (iohexol)
Study: 1535877
Drug: Low-dose nonionic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nonionic contrast medium (iohexol)
Study: 6526201
Drug: Isosorbide Dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide Dinitrate Ointment (ISDN-O): 300 mg daily
Study: 30878411
Drug: Low-dose nebulized
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nebulized epinephrine (0.1 mg/kg; maximum 1 mg)
Study: 30878411
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose nebulized epinephrine (0.5 mg/kg; maximum 5 mg)
Study: 26957110
Drug: GS-9857 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-9857 (100 mg once daily for 3 days)
Study: 26957110
Drug: GS-9857 (50-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-9857 (50-300 mg once daily for 3 days)
Study: 18059586
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (400 IU vitamin E + 1 g vitamin C)
Study: 12794024
Drug: Pentoxifyllin (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifyllin (PTX) 30 mg/kg/day
Study: 10695096
Drug: nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nifedipine GITS 20 mg once daily
Study: 12239234
Drug: Fosinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (20 mg)
Study: 25662474
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment (2-day admission)
Study: 17577468
Drug: Intravenous/oral linezolid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous/oral linezolid
Study: 7698835
Drug: 0.25% prednicarbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% prednicarbate cream used twice daily over 5 days
Study: 7698835
Drug: 0.25% prednicarbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% prednicarbate cream with didecyldimethylammoniumchloride
Study: 2937812
Drug: Ciprofloxacin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 1,000 mg
Study: 2937812
Drug: Ciprofloxacin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (all doses)
Study: 27814869
Drug: Neurodynamic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodynamic treatment (four sessions over two weeks comprising passive lumbar foramen opening and neurodynamic sliders plus home exercises)
Study: 25357122
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of spraying and eliminating dogs
Study: 23837404
Drug: Deworming and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deworming and weekly iron supplementation for 6 months
Study: 10933355
Drug: Ramipril (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5-10 mg daily)
Study: 9024334
Drug: Cholinergic agents
Normalized name: ANTICHOLINERGIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinergic agents (cholinesterase inhibitors)
Study: 9024334
Drug: Antioxidants, monoamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants, monoamine oxidase‐B inhibitors, cholinesterase inhibitors, anti‐inflammatory agents
Study: 9024334
Drug: Drugs that
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs that improve cognition
Study: 1316061
Drug: Lomefloxacin 400
Normalized name: lomefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin 400 mg orally 2‐6 hours prior to surgery
Study: 1316061
Drug: Cefotaxime 1
Normalized name: cefotaxime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 1 g intravenously or intramuscularly 30‐90 minutes preoperatively
Study: 7462679
Drug: 8-methoxypsoralen (8-MOP)
Normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-methoxypsoralen (8-MOP) 0.3 mg/kg
Study: 7462679
Drug: 8-methoxypsoralen (8-MOP)
Normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-methoxypsoralen (8-MOP) 0.6 mg/kg
Study: 7462679
Drug: 8-methoxypsoralen (8-MOP)
Normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-methoxypsoralen (8-MOP) 0.9 mg/kg
Study: 28741653
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate syrup 50 mg.kg-1
Study: 28741653
Drug: Intranasal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal saline spray (control)
Study: 28741653
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine spray 3 μg.kg-1
Study: 28741653
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate syrup and placebo spray
Study: 25321659
Drug: Omega-3 supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplements (4.0 g/d eicosapentaenoic acid and 2.0 g/d docosahexaenoic acid)
Study: 19303968
Drug: Pulsatile intravenous
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile intravenous insulin therapy
Study: 17217712
Drug: xuezhikang (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: xuezhikang (1200 mg/d)
Study: 14513420
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy regimen 1
Study: 14513420
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy regimen 2
Study: 14513420
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy regimen 3
Study: 6750781
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc sulphate
Study: 26029816
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (Havrix™, GSK, Belgium)
Study: 19909979
Drug: Fludrocortisone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone (0.2 mg/d)
Study: 18227107
Drug: Treatment effects
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effects in trials with allocation concealment
Study: 15840761
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of diazepam
Study: 12574578
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO) at 2.5 ATA for 60 minutes
Study: 12574578
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment at 1.14 ATA
Study: 10707873
Drug: rHuIL-12 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuIL-12 (all doses)
Study: 31171016
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (125 mL taken twice daily for 12 weeks)
Study: 31171016
Drug: Placebo (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (125 mL taken twice daily for 12 weeks)
Study: 20934829
Drug: Intramuscular piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular piroxicam (20 mg)
Study: 11410192
Drug: Deltamethrin insecticide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deltamethrin insecticide treatment applied to livestock during the malaria transmission seasons.
Study: 11410192
Drug: Deltamethrin insecticide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deltamethrin insecticide treatment applied to livestock.
Study: 11410192
Drug: Deltamethrin insecticide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deltamethrin insecticide treatment applied to livestock in a highly endemic settlement.
Study: 9404682
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate treatment with diet only (Group I)
Study: 9404682
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate treatment with oral hypoglycemic agents (OHA) (Group II)
Study: 9404682
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate treatment with insulin (Group III)
Study: 8234998
Drug: Nitroglycerin patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin patches (10 mg/day)
Study: 8234998
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with nitroglycerin patches
Study: 8234998
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment with nitroglycerin patches
Study: 3548602
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose steroid regimen
Study: 25047497
Drug: Lobeglitazone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobeglitazone 0.5 mg with ketoconazole (9 doses of 200 mg pretreatment twice daily)
Study: 25047497
Drug: Lobeglitazone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobeglitazone 0.5 mg without ketoconazole
Study: 22418661
Drug: MF59-adjuvanted vaccines
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted vaccines
Study: 22418661
Drug: Nonadjuvanted vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted vaccines
Study: 22418661
Drug: Vaccine with
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine with 7.5 µg antigen and full dose of MF59
Study: 18025250
Drug: Atomoxetine (10-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (10-week treatment)
Study: 11303372
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose interleukin-2 (IL-2) therapy, 720,000 IU/kg per dose i.v. in 15 minutes, administered in bolus for 2 weeks with a 1 week rest interval.